靶向抗肿瘤前药系统的研究进展  

Study Progress of Targeting Anticancer Prodrug System

作　　者：张丹妮 

机构地区：[1]锦州市妇婴医院,辽宁锦州121000

出　　处：《辽宁医学院学报》2013年第5期88-90,共3页Journal of Liaoning Medical University (LNMU) Bimonthly

摘　　要：世界上约10%被批准的药物可归类为前药。前药是一类在体外无生物活性或低生物活性,可在体内经生物转化释放出原药而发挥药物毒作用的物质。前药设计主要是用来改善药物的物化、生物学和药代动力学性质。本文主要综述前药在肿瘤靶向治疗理念中的研究进展,主要包括抗体导向的酶前药疗法(antibody directed enzyme prodrug therapy,ADEPT)和基因导向的酶前药疗法(gene directed enzyme prodrug therapy,GDEPT)等。About 10% of the approved drugs worldwide can be classified as prodrugs. Prodrug, a kind of substance with no biological activities or inactive biological activities in vitro, can release active compound and become toxicity sub- stance through biotransformation in vivo. Prodrug design is primarily used for improving the properties of physic - chemis- try, biology and pharmacokinetics. This paper summarizes the research progress of prodrugs in treating targeting tumor, in- cluding antibody directed enzyme prodrug therapy （ADEPT） and gene directed enzyme prodrug therapy （GDEPT）.

关 键 词：前药 靶向 ADEPT GDEPT 

分 类 号：R730.5[医药卫生—肿瘤]